VERU

Veru Inc. is a biopharmaceutical company focused on developing medicines for cardiometabolic and inflammatory diseases. Its drug development program includes two late-stage new chemical entities: enobosarm, an oral selective androgen receptor modulator (SARM) aimed at augmenting fat loss and preventing muscle loss in older patients, and sabizabulin, an oral microtubule disruptor being developed as an anti-inflammatory agent to address atherosclerotic cardiovascular disease. Veru operates primarily in the healthcare sector, targeting patients with obesity and coronary artery disease.